secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001493152-24-044224
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025
--------------------------------------------------------------------------------

- Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
- Vaccine safe and well tolerated; only notable side effect was injection-site irritation.
- Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).
- Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.
- Phase 2 neoadjuvant study with randomized control planned to commence in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/0001493152-24-044224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer